Vivreon Biosciences, LLC
Publicly observedSan Diego, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Diego | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Vivreon Biosciences, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | P935LHN98ZV9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jul 2025Publicly observed
NIH SBIR/STTR award: Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
USD 1,948,898.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jul 2025Publicly observed
NIH SBIR/STTR award: Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
USD 1,996,385.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant15 Jul 2023Publicly observed
NIH SBIR/STTR award: Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder
USD 1,097,854.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
- Grant1 May 2022Publicly observed
NIH SBIR/STTR award: Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
USD 999,997.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.